C4 Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical juncture, balancing a well-funded balance sheet against a dwindling revenue base. The net loss of $25.1 million and a quarterly cash burn of nearly $30 million underscore the high cost of clinical development. While the reduction in R&D spend suggests a more focused approach, the termination of the Merck agreement and the shift in MKDG priorities highlight the inherent volatility of the biotech partnership model. Ultimately, the investment thesis now rests entirely on the binary outcomes of the MOMENTUM trial and the successful execution of the Pfizer and Roche collaborations. The $268 million war chest buys the company time, but the massive warrant overhang creates a ceiling for the stock price unless the clinical data is overwhelmingly positive. Investors are now trading a high-risk, high-reward clinical catalyst play where the margin for error has narrowed significantly.